NCT03373487

Brief Summary

Many patients with primary brain tumors experience cognitive deficits and cognitive rehabilitation programs aim to alleviate these deficits.The cognitive rehabilitation program developed by the investigators proved effective in a large randomized controlled trial (RCT). To increase its accessibility, it was converted into the iPad-based cognitive rehabilitation program ReMind, which incorporates psychoeducation, strategy training and retraining. A pilot study and a randomized controlled trial are conducted, to evaluate the feasibility of the use of the program and the efficacy of the program in brain tumor patients after resective surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
115

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2015

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

September 5, 2017

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 14, 2017

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2019

Completed
Last Updated

February 13, 2018

Status Verified

October 1, 2017

Enrollment Period

4 years

First QC Date

September 5, 2017

Last Update Submit

February 12, 2018

Conditions

Outcome Measures

Primary Outcomes (3)

  • Change in objective cognitive functioning

    Objective cognitive functioning is measured with the computerized test battery CNS Vital Signs

    3, 6, and 12 months after surgery

  • Change in working memory

    Working memory is measured with the subtest Digit Span of the the Wechsler Adult Intelligence Scale (WAIS-III)

    3, 6, and 12 months after surgery

  • Change in word fluency

    Word fluency is measured with the Letter Fluency test

    3, 6, and 12 months after surgery

Secondary Outcomes (8)

  • Change in subjective cognitive functioning

    3, 6, and 12 months after surgery

  • Change in symptoms of fatigue

    3, 6, and 12 months after surgery

  • Change in symptoms of anxiety

    3, 6, and 12 months after surgery

  • Change in symptoms of depression

    3, 6, and 12 months after surgery

  • Change in subjective executive functioning

    3, 6, and 12 months after surgery

  • +3 more secondary outcomes

Study Arms (2)

Early-intervention group

EXPERIMENTAL

Patients follow the evidence-based cognitive rehabilitation program ReMind, which is provided via an iPad. It incorporates psychoeducation, strategy training and retraining. The intervention commenced 3 months after surgery and patients were advised to spend 3 hours per week on the program for 10 weeks.

Behavioral: The cognitive rehabilitation program ReMind

Waiting-list control group

OTHER

The waiting-list control group will be offered the same cognitive rehabilitation program after they have undergone all study assessments one year after surgery.

Behavioral: The cognitive rehabilitation program ReMind

Interventions

Cognitive rehabilitation, i.e. psychoeducation, strategy training \& retraining

Also known as: ReMind-app
Early-intervention groupWaiting-list control group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The adult patient has a (supratentorial or infratentorial) brain tumor that is radiologically suspect for either a meningioma or low grade glioma
  • The patient will undergo resective surgery for the brain tumor

You may not qualify if:

  • tumor resection in the last year
  • progressive neurological disease
  • diagnose of (acute) psychiatric or neurological disorders in the last 2 years
  • chemotherapy in the last 2 years
  • Karnovsky Performance Scale under 70
  • Surgery-related complication (morbidity or mortality e.g., thrombosis or heart attack)
  • Lack of basic proficiency in Dutch
  • IQ below 85, or (very) low cognitive skills
  • Insufficient reading skills/visual impairment (limiting the ability to follow the cognitive rehabilitation program).
  • Clinical referral to cognitive rehabilitation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Erasmus Medical Center

Rotterdam, Netherlands

RECRUITING

Medical Center Haaglanden

The Hague, Netherlands

RECRUITING

Elisabeth-TweeSteden Hospital

Tilburg, 5022 GC, Netherlands

RECRUITING

MeSH Terms

Conditions

Brain NeoplasmsCognitive Dysfunction

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCognition DisordersNeurocognitive DisordersMental Disorders

Central Study Contacts

Karin Gehring, PhD

CONTACT

Sophie D van der Linden, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Well-trained research assistants, who are conducting neuropsychological assessments, are blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 5, 2017

First Posted

December 14, 2017

Study Start

July 1, 2015

Primary Completion

June 30, 2019

Study Completion

June 30, 2019

Last Updated

February 13, 2018

Record last verified: 2017-10

Locations